Status:
NOT_YET_RECRUITING
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead Sponsor:
RemeGen Co., Ltd.
Conditions:
Gastric Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of \*\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\*\* as first-line treatment for p...
Eligibility Criteria
Inclusion
- Voluntarily consent to participate in the study and sign the informed consent form
- Expected survival period \>12 weeks
- ECOG Performance Status 0 or 1
- Histologically confirmed unresectable locally advanced, metastatic, or recurrent gastric or gastroesophageal junction adenocarcinoma
- No prior systemic therapy for locally advanced or metastatic gastric cancer
- HER2-low expression
- At least one assessable lesion according to RECIST v1.1 criteria
- Adequate organ function
- For female subjects: They should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive method (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and for 6 months after the end of the study treatment. A blood pregnancy test must be negative within 7 days before the study medication is administered, and they must not be breastfeeding
- For male subjects: They should be surgically sterilized or agree to use a medically approved contraceptive method during the study treatment period and for 6 months after the end of the study treatment
- Able to understand the study requirements and willing to comply with the study and follow-up procedures
Exclusion
- Presence of central nervous system (CNS) metastasis and/or carcinomatous meningitis
- Peripheral neuropathy \> Grade 1
- Tumor lesions with a tendency to bleed
- Uncontrolled diarrhea
- Bone metastases with a risk of paraplegia
- Past or current interstitial lung disease, or presence of drug-induced pneumonia, radiation pneumonia, or severely impaired lung function
- Other malignancies within 5 years before the first dose, except for those expected to be cured with treatment (e.g., adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery)
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
May 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 15 2030
Estimated Enrollment :
616 Patients enrolled
Trial Details
Trial ID
NCT06944496
Start Date
May 15 2025
End Date
May 15 2030
Last Update
April 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, BJ-Beijing, China, 100021